Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Arch Soc Esp Oftalmol (Engl Ed) ; 99(3): 98-108, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38216051

RESUMO

BACKGROUND AND OBJECTIVE: Recommendations on general glaucoma management and the use of early minimally invasive and microincisional surgeries are limited. This study aimed to establish consensus regarding glaucoma management, focusing on the XEN-45 gel stent implant. METHODS: A Delphi consensus-driven process was used. The scientific committee led the study, identified the expert panel, and participated in elaborating the questionnaire. Fifty-one panelists were invited to complete, on a nine-point Likert scale, an 89-item questionnaire covering three topic blocks. Two Delphi rounds were performed. Consensus was achieved if ≥66.6% of panelists reached agreement or disagreement. RESULTS: Panelists agreed on 84 items related to the patients' quality of life, the therapeutic algorithm and patient profile, and surgical and pre- and post-operative management. Panelists agreed on the suitability of XEN stent implants to treat glaucoma at different stages and for different patient profiles: young patients, elderly or with significant comorbidities, and with myopic glaucoma, patients who failed previous surgeries, and with previous poor post-operative experience. XEN surgery was considered a therapeutic step prior to classic filtering surgery and a possible first surgical option in elderly patients with comorbidities and uncontrolled intraocular pressure. XEN surgery allows the patient to return to routine daily activities faster than conventional filtering surgeries and to reduce and/or eliminate topical treatments. CONCLUSIONS: This Delphi-driven consensus resulted in a series of general recommendations for glaucoma management, including those related to patient quality of life, therapeutic algorithm, and patient profile, and specific ones regarding the use of XEN stent gel surgery.


Assuntos
Implantes para Drenagem de Glaucoma , Glaucoma , Humanos , Idoso , Técnica Delphi , Qualidade de Vida , Resultado do Tratamento , Glaucoma/cirurgia
2.
Rev. cuba. pediatr ; 952023. ilus, tab
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1515282

RESUMO

Introducción: La inflamación de la pleura desencadenada por bacterias y mediada por citocinas, aumenta la permeabilidad vascular y produce vasodilatación, lo cual genera desequilibrio entre la producción de líquido pleural y su capacidad de reabsorción por eficientes mecanismos fisiológicos. La condición anterior conduce al desarrollo de derrame pleural paraneumónico. Objetivo: Exponer la importancia de la correlación fisiopatológica y diagnóstica con los pilares fundamentales de actuación terapéutica en el derrame pleural paraneumónico. Métodos: Revisión en PubMed y Google Scholar de artículos publicados hasta abril de 2021 que abordaran el derrame pleural paraneumónico, su fisiopatología, elementos diagnósticos, tanto clínicos como resultados del estudio del líquido pleural, pruebas de imágenes, y estrategias terapéuticas. Análisis y síntesis de la información: El progreso de una infección pulmonar y la producción de una invasión de gérmenes al espacio pleural favorece la activación de mecanismos que conllevan al acúmulo de fluido, depósito de fibrina y formación de septos. Este proceso patológico se traduce en manifestaciones clínicas, cambios en los valores citoquímicos y resultados microbiológicos en el líquido pleural, que acompañados de signos radiológicos y ecográficos en el tórax, guían la aplicación oportuna de los pilares de tratamiento del derrame pleural paraneumónico. Conclusiones: Ante un derrame pleural paraneumónico, con tabiques o partículas en suspensión en la ecografía de tórax, hallazgo de fibrina, líquido turbio o pus en el proceder de colocación del drenaje de tórax, resulta necesario iniciar fibrinólisis intrapleural. Cuando el tratamiento con fibrinolíticos intrapleurales falla, la cirugía video-toracoscópica es el procedimiento quirúrgico de elección(AU)


Introduction: The inflammation of the pleura triggered by bacteria and mediated by cytokines, increases vascular permeability and produces vasodilation, which generates imbalance between the production of pleural fluid and its resorption capacity by efficient physiological mechanisms. The above condition leads to the development of parapneumonic pleural effusion. Objective: To expose the importance of the pathophysiological and diagnostic correlation with the fundamental pillars of therapeutic action in parapneumonic pleural effusion. Methods: Review in PubMed and Google Scholar of articles published until April 2021 that addressed parapneumonic pleural effusion, its pathophysiology, diagnostic elements, both clinical and results of the pleural fluid study, imaging tests, and therapeutic strategies. Analysis and synthesis of information: The progress of a lung infection and the production of an invasion of germs into the pleural space favors the activation of mechanisms that lead to the accumulation of fluid, fibrin deposition and formation of septa. This pathological process results in clinical manifestations, changes in cytochemical values and microbiological results in the pleural fluid, which accompanied by radiological and ultrasound signs in the chest, guide the timely application of the pillars of treatment of parapneumonic pleural effusion. Conclusions: In the event of a parapneumonic pleural effusion, with septums or particles in suspension on chest ultrasound, finding fibrin, turbid fluid or pus in the procedure of placement of the chest drain, it is necessary to initiate intrapleural fibrinolytic. When treatment with intrapleural fibrinolytics fails, video-thoracoscopic surgery is the surgical procedure of choice(AU)


Assuntos
Humanos , Derrame Pleural/classificação , Derrame Pleural/fisiopatologia , Derrame Pleural/tratamento farmacológico , Derrame Pleural/diagnóstico por imagem , Drenagem/instrumentação , Antibacterianos
3.
Insuf. card ; 14(supl.1): 1-7, mar. 2019. ilus, tab
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1002164

RESUMO

La hipertensión arterial pulmonar es una enfermedad infrecuente, caracterizada por el aumento de postcarga del ventrículo derecho. La adaptación del ventrículo derecho a esta postcarga se relaciona con el pronóstico de los pacientes. La estratificación pronóstica se basa en una valoración multiparamétrica. Los parámetros clínicos, funcionales, la valoración del ventrículo derecho y la evaluación hemodinámica van a definir la situación de riesgo de los pacientes, en función de la mortalidad a un año. La situación de bajo riesgo a un año de seguimiento se ha relacionado con mayor supervivencia. El algoritmo terapéutico actual incluye como estrategia inicial la mono, doble y triple terapia. Se debe realizar escalada terapéutica con el objetivo de mantener a los pacientes en bajo riesgo durante el seguimiento.


Pulmonary arterial hypertension is an infrequent disease, characterized by an increase in afterload of the right ventricle. The adaptation of the right ventricle to this afterload is related to the prognosis of the patients. The prognostic stratification is based on a multiparametric assessment. The clinical, functional parameters, assessment of the right ventricle and hemodynamic evaluation will define the risk situation of the patients, depending on the one-year mortality. The situation of low risk at one year of follow-up has been related to greater survival. The current therapeutic algorithm includes monotherapy, double and triple therapy as an initial strategy. Therapeutic escalation should be carried out in order to keep patients at low risk during follow-up.


A hipertensão arterial pulmonar é uma doença infreqüente, caracterizada por aumento da pós-carga do ventrículo direito. A adaptação do ventrículo direito a essa pós-carga está relacionada ao prognóstico dos pacientes. A estratificação prognóstica é baseada em uma avaliação multiparamétrica. Os parâmetros clínicos, funcionais, avaliação do ventrículo direito e avaliação hemodinâmica definirão a situação de risco dos pacientes, dependendo da mortalidade em um ano. A situação de baixo risco em um ano de seguimento tem sido relacionada à maior sobrevida. O algoritmo terapêutico atual inclui como estratégia inicial a monoterapia e a terapia dupla e tripla. O escalonamento terapêutico deve ser realizado a fim de manter os pacientes em baixo risco durante o acompanhamento.

4.
Actas Dermosifiliogr ; 108(4): e27-e32, 2017 May.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-28110827

RESUMO

Eccrine porocarcinoma is a rare, malignant cutaneous adnexal tumor that arises from the ducts of sweat glands. Found mainly in patients of advanced age, this tumor has diverse clinical presentations. Histology confirms the diagnosis, detects features relevant to prognosis, and guides treatment. Growth is slow, but the prognosis is poor if the tumor metastasizes to lymph nodes or visceral organs. We report 7 cases of eccrine porocarcinoma, describing patient characteristics, the clinical and histopathologic features of the tumors, and treatments used. Our observations were similar to those of other published case series. Given the lack of therapeutic algorithms or protocols for this carcinoma, we propose a decision-making schema based on our review of the literature and our experience with this case series. The algorithm centers on sentinel lymph node biopsy and histologic features.


Assuntos
Porocarcinoma Écrino , Neoplasias das Glândulas Sudoríparas , Adulto , Idoso , Idoso de 80 Anos ou mais , Tomada de Decisão Clínica , Gerenciamento Clínico , Porocarcinoma Écrino/diagnóstico , Porocarcinoma Écrino/patologia , Porocarcinoma Écrino/secundário , Porocarcinoma Écrino/terapia , Feminino , Humanos , Excisão de Linfonodo , Metástase Linfática/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Prognóstico , Radioterapia Adjuvante , Biópsia de Linfonodo Sentinela , Neoplasias das Glândulas Sudoríparas/diagnóstico , Neoplasias das Glândulas Sudoríparas/cirurgia , Neoplasias das Glândulas Sudoríparas/terapia
5.
Dolor ; 19(53): 34-53, jul. 2010. tab
Artigo em Espanhol | LILACS | ID: lil-682508

RESUMO

Con la introducción y el desarrollo de nuevos productos que han demostrado ser eficaces en el dolor neuropático (DN), se ha generado una clara necesidad de tener un algoritmo basado en la evidencia para tratar las diferentes condiciones del DN. El objetivo de este artículo es elaborar unas recomendaciones para el tratamiento del DN que estén avaladas por la evidencia científica y que estén consensuadas por un grupo multidisciplinario de expertos en metodología y en tratamiento del dolor. La evidencia se ha obtenido de estudios de metanálisis que recogen la mayor información disponible para cada tipo de DN. La búsqueda bibliográfica se llevó a cabo por 5 revisores, que se centraron individualmente en las diferentes formas de presentación del DN. Las bases de datos consultadas fueron la Cochrane Library, EMBASE (año 2000 en adelante) y PUBMED(año 2000 en adelante), y se seleccionaron metaanálisis y ensayos clínicos aleatorizados y controlados. Finalmente, los autores, especialistas en dolor, evaluaron e hicieron las recomendaciones clínicas para el tratamiento del DN. En algunos tipos de DN, de los cuales no hay suficiente información, se han incluido recomendaciones basadas en publicaciones científicas sin evidencia, con el objetivo de que estas recomendaciones proporcionen la mayor información posible acerca de su tratamiento. Se han revisado estudios de eficacia y seguridad de neuralgia postherpética (NPH), neuropatía diabética dolorosa (NDD) y neuralgia del trigémino(NT) como paradigmas de DN periférico, y también se ha recogido la escasa información existente acerca del DN central(DNC) y el dolor simpático (DS). Con los resultados obtenidos con este estudio bibliográfico y las evidencias extraídas, se ha elaborado un algoritmo de decisión con los fármacos disponibles actualmente en la farmacopea española para la NPH y la NDD; por otro lado, y de forma independiente, para la NT y, finalmente, para el DNC y el DS.


The introduction and development of new products with demonstrated efficacy in neuropathic pain has generated a clear need for an evidence-based algorithm to treat the different types of neuropathic pain. The present article aims to provide recommendations on the treatment of neuropathic pain supported by the scientific evidence and agreed on by consensus by a multidisciplinary group of experts in methodology and pain management. The evidence was obtained from meta-analyses including the greatest amount of information available for each type of neuropathic pain. The literature search was performed by 5 reviewers, who focussed individually on the distinct forms of presentation of neuropathic pain. The databases consulted were the Cochrane Library, EMBASE (from 2000 onwards), and PUBMED (from 2000 onwards). Meta-analyses and randomized, controlled clinical trials were selected. Finally, retrieved articles were evaluated and clinical recommendations for the treatment of neuropathic pain were designed by the pain specialists. For some types of neuropathic pain, there is insufficient information. In these types of pain, recommendations based on scientific publications without evidence were included to provide the reatest possible amount of information on their treatment. Studies of safety and efficacy in postherpetic neuralgia (PHN), painful diabetic neuropathy (PDN), and trigeminal neuralgia (TN) were reviewed as paradigms of peripheral neuropathic pain. The scarce available information on central neuropathic pain (CNP) and sympathetic pain (SP) was also gathered. Based on the results obtained with this literature review and the evidence extracted, a decision algorithm was designed with the drugs currently available in the Spanish pharmacopeia for PHN and PDN, and separate decision algorithms were designed for TN and finally for CNP and S P.


Assuntos
Humanos , Analgésicos/uso terapêutico , Anestésicos/uso terapêutico , Neuralgia/tratamento farmacológico , Algoritmos , Neuralgia Pós-Herpética/tratamento farmacológico , Neuralgia do Trigêmeo/tratamento farmacológico , Neuropatias Diabéticas/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA